8-K: Ovid Therapeutics Announces Positive Progress in Clinical Pipeline and First Quarter 2025 Financial Results

Ovid Therapeutics reports advancements in its clinical pipeline, including progress in Phase 1 studies for OV329 and OV350, along with a cash runway extending into the second half of 2026.

Summary

• Ovid Therapeutics reported its business updates and financial results for the first quarter ended March 31, 2025.
• Topline pharmacodynamic biomarker, safety, and tolerability results from a Phase 1 study of OV329 are expected in Q3 2025.
• OV350, Ovid's first program in its KCC2 direct activator library, has been dosed in a Phase 1 study in Q1 2025, with safety and tolerability results expected before year-end.
• The company's cash, cash equivalents, and marketable securities totaled $43.0 million as of March 31, 2025, which is expected to support operations and development programs into the second half of 2026.
• Revenues from royalty agreements were $130,000 for the first quarter ended March 31, 2025, compared to $148,000 in the same period in 2024.
• Research and development expenses were $6.7 million for the first quarter ended March 31, 2025, compared to $10.4 million in the same period in 2024.
• General and administrative expenses were $6.0 million for the first quarter ended March 31, 2025, compared to $7.2 million for the same period in 2024.
• Ovid reported a net loss of $10.2 million, or $0.14 per share, for the first quarter of 2025, compared to a net loss of $11.7 million, or $0.17 per share, for the same period in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, sufficient cash runway, and cost-saving efforts. However, the net loss and decreased royalty revenues temper the overall outlook.

Positives

• Ovid has a strong cash position of $43.0 million, expected to fund operations into the second half of 2026.
• The company is advancing its clinical pipeline with multiple programs in Phase 1 and plans for Phase 2 trials.
• Ovid is exploring partnerships and other opportunities to accelerate development and offset costs.
• The company is managing its clinical development programs, operations, and cash expenditures with fiscal discipline.
• Net loss decreased from $11.7 million in Q1 2024 to $10.2 million in Q1 2025.

Negatives

• Ovid reported a net loss of $10.2 million for the first quarter of 2025.
• Revenues from royalty agreements decreased from $148,000 in Q1 2024 to $130,000 in Q1 2025.

Risks

• The company's future results are subject to uncertainties inherent in preclinical and clinical development and regulatory approval processes.
• Ovid's ability to achieve expected benefits of cost-savings efforts is not guaranteed.
• The company faces risks related to its ability to achieve its financial objectives and execute its business strategy.
• Macroeconomic and geopolitical conditions could have unanticipated or greater than anticipated impacts or delays.

Future Outlook

Ovid expects its cash runway to support operations and clinical development programs into the second half of 2026, with multiple pipeline and regulatory milestones anticipated.

Management Comments

• Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics, stated that the company is off to a strong start across its pipeline and programs in what will be a defining year for Ovid.
• Dr. Levin noted that OV329 continues to show promise as a potential next-generation medicine for treatment resistant seizures.
• Dr. Levin mentioned that Ovid has initiated human trials of its first-in-class KCC2 direct activator.

Industry Context

Ovid's focus on small molecule medicines for brain conditions aligns with the growing interest in targeted therapies for neurological and neuropsychiatric disorders. The development of KCC2 direct activators represents a novel approach to addressing neural hyperexcitability, a common factor in many CNS disorders.

Comparison to Industry Standards

• Ovid's approach to developing OV329, a next-generation GABA-AT inhibitor, aims to improve upon the safety and tolerability profile of vigabatrin, a first-generation GABA-AT inhibitor.
• The company's focus on KCC2 direct activators is a novel approach compared to traditional treatments for neurological disorders, potentially offering a new mechanism of action.
• Other companies in the CNS space include companies such as Biogen, Takeda, and UCB, which are developing treatments for epilepsy and other neurological disorders.

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials and the company's cash position.
• Employees may be affected by the organizational restructuring and cost-reduction efforts.
• Patients with neurological disorders may benefit from the development of new treatments.
• Partners and collaborators may be interested in the potential for co-development and regional opportunities.

Next Steps

• Ovid expects to readout topline results for OV329 in Q3 2025.
• The company intends to take up to two doses of OV329 into an adaptive Phase 2a trial design in adults with treatment resistant focal seizures.
• Ovid intends to leverage PD/PK findings from OV350 to inform its oral KCC2 program, OV4071.
• Ovid is conducting IND-enabling and formulation efforts for three unique KCC2 direct activator molecules from its larger library.
• Ovid expects to initiate a proof-of-concept trial for OV4071 in H1 2026.

Key Dates

Keywords

Ovid Therapeutics, OV329, OV350, OV4071, KCC2 direct activator, GABA-AT inhibitor, Epilepsy, Seizures, Psychosis, Clinical trials, Financial results, Biopharmaceutical